We have developed a model system for studying the while retaining kinase activity. Because it is implicated cellular response to inhibition of v-erbB in a situation in in a large number of malignancies, EGFR provides an which the kinase inhibitor is specific for the oncogene. attractive target for such selective kinase inhibition.
transduced cells in soft agar. The IC 50 for NaPP1-mediated growth inhibition in this assay was between 0.5 and 1 M and was consistent with the range of concentration required to inhibit basal v-erbB-as1 phosphorylation ( Figure 1A) .
Mice injected subcutaneously with v-erbB or v-erbBas1 cells formed tumors of similar size at similar latencies ( Figure 1C ). NaPP1 completely blocked tumor formation in 5 of 6 mice that were injected subcutaneously with v-erbB-as1 cells and subjected to daily intraperitoneal injections of NaPP1 for 19 days. One of 6 mice in this cohort showed only partial blockage of tumor growth and developed a tumor of approximately 20% the size of untreated controls. Tumors from mice injected with v-erbB cells were unaffected by treatment with NaPP1 ( Figure 1C) . These experiments demonstrated that v-erbB-as1 kinase activity induced tumor formation and that tumor growth could be blocked by the selective inhibitor NaPP1.
We next asked whether NaPP1 could reverse preestablished transformation mediated by v-erbB-as1. Figure 1A shows that NaPP1 reversed tyrosine phosphorylation of v-erbB-as1-transformed cells in a dosedependent manner. At 2 M NaPP1, cells transduced with v-erbB-as1 showed full reduction of overall tyrosine phosphorylation to the level seen in cells transduced with empty vector ( Figure 1A ). There was no detectable decrease in the phosphorylation of cells transduced with v-erbB in response to treatment with 2 M NaPP1.
NaPP1 Transiently Blocks Signaling Downstream from v-erbB and Reverses Morphologic and Cytoskeletal Abnormalities
Signaling by v-erbB is mediated at least in part through the activation of MAP kinase/extracellular signal-regulated kinase 1,2 (ERK 1,2) and PI3/Akt kinase pathways (reviewed in [18] ). We therefore examined the status of these pathways in cells transduced with v-erbB and v-erbB-as1. nontransformed controls (Figures 2A and 2D) . In response to 48 hr NaPP1 treatment, cells transformed with v-erbB-as1 reverted to a pattern comparable to that of nontransformed NIH3T3 cells ( Figures 2C and 2D ). In observations suggest that the rounding up of cells during transformation by v-erbB-as1 is more strongly influcontrast, cells transformed with v-erbB retained a transformed morphology after treatment with NaPP1 (data enced by MAP kinase than by PI(3) kinase. not shown).
To explore the role of these signaling pathways in NaPP1 Treatment of v-erbB-as1 and v-Src-as1 Cells Leads to G 0 -G 1 Arrest morphological transformation, v-erbB-as1 cells were treated with the monospecific v-erbB-as1 inhibitor In response to NaPP1, fibroblasts transformed by v-erbB-as1 showed morphological reversal of transforNaPP1, with LY294002 (a relatively selective inhibitor of PI(3) kinase [19, 20] ), or with PD098509, a relatively mation and recovery of basal signaling through MAP kinase and PI(3) kinase. Surprisingly however, these selective inhibitor of MEK1 [21] . PD098509 restored levels of actin stress fibers in a manner comparable to cells did not proliferate, even after 48 hr when the activities of mitogenic kinases were restored (Figure 2 ). Cells NaPP1 (Figures 2G and 2H) . In contrast, LY294002, at a dose sufficient for inhibiting Akt activity ( Figure 2J) , transformed with v-erbB-as1 accumulated in G 0 -G 1 phase of the cell cycle after 24 hr of exposure to NaPP1, showed no effect on actin stress fibers ( Figure 2I ). These cells with v-erbB-as1 and added NaPP1 at 0, 3, 6, 12, 24, and 48 hr after transduction. Puromycin was added at 48 hr, and puromycin-resistant cells were counted at day 10. Addition of NaPP1 up to 12 hr after transduction of v-erbB-as1 had no effect on proliferation, whereas addition of NaPP1 at 24 hr and at later points resulted in proliferation arrest (our unpublished data).
This proliferation arrest was surprising because normal 3T3 cells proliferate in the absence of v-erbB-as1. One would therefore predict that NaPP1-treated v-erbBas1 cells should behave like normal 3T3 cells and continue to proliferate. If v-erbB-as1 heterodimerized with a growth factor receptor required for basal growth, then NaPP1 treatment of this heterodimer could lead to growth arrest. This scenario is unlikely because signaling through MAP kinase and PI(3) kinase pathways recovers after NaPP1 treatment, and such recovery should not occur if a growth factor receptor required for basal growth were blocked. Nevertheless, to address this concern further, we transduced retroviruses containing v-erbB or v-erbB-as1 into 3T3 cells grown continually in the presence of 2 M NaPP1 such that the v-erbBas1-transforming kinase was continuously inhibited. Puromycin-resistant v-erbB-as1 clones were readily selected from cells grown and transduced in the presence of NaPP1 ( Figure 3B ), suggesting that growth arrest was not secondary to a dominant-negative effect of NaPP1 in a v-erbB-as1 background.
To determine whether cell cycle arrest could be a general response to kinase inhibitor therapy, we per- Figure 1) . Injection of v-erbB-or v-erbB-as1-transduced leads to increased free p27, which binds and inactivates NIH3T3 cells into immunocompromised mice led to tuCdk2 and thereby blocks its ability to phosphorylate mor formation with comparable latencies. These three and degrade p27 [27] . experiments argue that the transforming potentials of To rule out the possibility that low levels of cyclin v-erbB and v-erbB-as1 are functionally equivalent. D1 were the result of cell cycle phase differences, we Treatment of transduced 3T3 or Rat1a cells with incubated v-erbB-as1 cells with antisera to cyclin D1 NaPP1 blocked transformation by v-erbB-as1 and had and visualized these by confocal microscopy. Figures no demonstrable effect on v-erbB. Treatment of mice 6A and 6B show that nuclear cyclin D1 levels were reinjected with these cells similarly impacted v-erbB-as1 duced dramatically by NaPP1 treatment. We next transwith no effect on v-erbB. These data demonstrate that duced cyclin D1 into v-erbB-as1 cells. NaPP1 treatment NaPP1 selectively inhibited v-erbB-as1 but had no of these cells did not arrest proliferation, nor did it impact discernable effect on signaling mediated by v-erbB. Importantly, NaPP1 could also reverse both tyrsosine cyclin D1 levels. These experiments argue that cell cycle phosphorylation and the transformed morphology assocycle arrest in NaPP1-treated v-erbB-as1 cells, we demonstrated that NaPP1 had no impact on vector-transciated with v-erbB-as1 transduction of 3T3 cells (Figure 2) . formed cells, that NaPP1 treatment did not affect the transduction of v-erbB-as1, and that NaPP1 treatment of v-Src-as1 also caused proliferation arrest. Additionally, G 0 Arrest in Reversibly Transformed Cells PDGF efficiently supported growth of serum-starved Suggests that Cells Become Dependent on Aberrant v-erbB-as1 cells, and signaling through the PDGF recepOncogenic Signaling tor was intact in these cells even after NaPP1 treatment After treatment with NaPP1, transformed v-erbB-as1 arrested their growth. These data collectively argue that cells showed reduced signaling through MAP kinase G 0 arrest observed after NaPP1 treatment of cells transand PI(3) kinase, with subsequent recovery of basal miformed with either v-erbB-as1 or v-Src-as1 reflects the togenic signaling through both pathways. Despite the cells' dependence on aberrant signaling by the transapparent normalization of morphology and signaling in forming oncogene and that reversal of the initiating onthese cells, NaPP1 treatment of cells transduced with cogenic event by drug treatment was insufficient to v-erbB-as1 led to G 0 arrest, with reduced levels of D allow re-entry into the cell cycle. and A type cyclins and high levels of p27. Similar blockWe hypothesize that NaPP1-treated v-erbB-as1 and ade and subsequent recovery of MAP kinase signaling v-Src-as1 cells failed to proliferate because some ashas been described in cells made quiescent (in G 0 ) by pect of signaling has not been restored in these cells. growth in low serum [29] . Quiescence in serum-starved Further examination of reversible transformation in this cells was associated with cytoplasmic sequestration of simple v-erbB-as1-driven system should allow us to phosphorylated ERK, as well as with recovery of proliferidentify the critical determinants that underlie cell cycle ation upon addition of serum to the media [29] . Our arrest in response to NaPP1 treatment. In two experiresults with NaPP1-treated v-erbB-as1 cells demonments aimed at understanding the mechanism of cell strate that phospho-ERK was distributed in the cytocycle arrest in this system, we have shown that both plasm and nucleus (Figure 3) , suggesting that cytocyclin D1 and Raf restored proliferation in NaPP1-plasmic sequestration did not play a major role in the treated v-erbB-as1 cells (Figures 6 and 7) . These obser-G 0 arrest observed in these cells.
To exclude a dominant-negative mechanism of cell vations suggest the block in cell cycle signaling lies that other molecularly targeted agents may have similar efficacy. EGFR is an obvious candidate for kinase inhibitor therapy because it is implicated in a broad range of malignancies. Because most commonly used kinase inhibitors (including the new EGFR inhibitors now in clinical trials) also inhibit endogenous signaling pathways, one cannot differentiate between true oncogene-dependent events (such as those mediated by v-erbB) and the similar normal pathways (mediated through EGFR and other cellular kinases). By using analog-selective alleles of v-erbB and v-Src, as well as monoselective inhibitors of these alleles, we selectively blocked oncogenic signaling and could accurately distinguish normal from aberrant signaling. Using this approach, we showed that cells adapted rapidly to oncogenic signaling prior to the acquisition of secondary mutations in additional oncogenes or tumor suppressor genes. This adaptation shifted cells from normal growth factor control to oncogene-dependent growth. Others have shown that tumor growth in transgenic mice required continued signaling by the initiating oncogene [31] [32] [33] [34] . We here extend and in part explain these observations by showing that the original oncogene has really co-opted the cell signaling machinery. This adaptation happened on an extremely fast time scale and explains the continued dependence on signaling by the initiated oncogene (i.e., the cell has become addicted to the aberrant oncogenic signaling [35] ).
Our observations in rodent fibroblasts may help to explain the remarkable therapeutic index associated with Gleevec, a drug for which the maximum tolerated 
